---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-019062"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T03:05:42.745243+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Reviva reports positive full dataset from Phase 3 OLE study of brilaroxazine in schizophrenia

## Summary
- Brilaroxazine showed sustained efficacy across all symptom domains: PANSS total score improved -18.1 at 12 months (p≤0.001).
- Safety profile well-tolerated: 8.5% TEAEs mostly mild, no drug-related SAEs; discontinuation rate 35%.
- Mild weight gain (1.52 kg) and no clinically significant cardiac, liver, or metabolic side effects.
- Long-term safety data from 100 patients completing 1 year meets NDA submission requirement for FDA.
- Improved multiple neuroinflammatory biomarkers; virtual webcast held June 2, 2025 at 8:00 a.m. EDT.

## SEC filing metadata
- accession: 0001437749-25-019062
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774925019062/0001437749-25-019062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774925019062/rvph20250601_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-019062
- JSON: https://secwatch.observer/filing/0001437749-25-019062.json
- Plain text: https://secwatch.observer/filing/0001437749-25-019062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.